Search results
Novavax (NASDAQ:NVAX) PT Raised to $18.00
ETF DAILY NEWS· 8 hours agoThe firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Bank of America‘s price target would suggest a potential upside of 25.00% from the company ...
Is It Too Late to Buy Novavax Stock? | The Motley Fool
The Motley Fool· 2 days agoWith Novavax already accumulating such impressive gains this year (it's up 234%), is it too late to...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 3 days agoNovavax Stock A Buy? No, Novavax stock isn't a buy. Savvy investors are encouraged to buy a stock
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 2 days agoNovavax , Inc. (NASDAQ: NASDAQ:NVAX) has announced its submission for an amended Emergency Use...
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June...
Benzinga· 7 days agoMid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX,...
Abbott Labs Enters The U.S. Obesity Arena
Investor's Business Daily· 6 days agoAbbott Laboratories (ABT) gained U.S. clearance Monday for a pair of new continuous glucose monitors. The Food and Drug Administration signed off on...
12 Health Care Stocks Moving In Monday's Intraday Session - Curis (NASDAQ:CRIS), CNS Pharma...
Benzinga· 6 days agoSkye Bioscience SKYE stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. Novavax NVAX shares decreased by 14.62% ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 4 days agoThat compares to 55.6% for Keytruda alone. Earlier in the year, one analyst called results from the...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 4 days agoIt will be important to watch how Pfizer stock performs as the company shores up its pipeline and...
Moderna Falls, Though Says Covid/Flu Shot Topped Rivals
Investor's Business Daily· 6 days agoIn a study of about 8,000 people, Moderna's combination vaccine proved it's not inferior to the...
